Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Phone app aims to keep lung cancer patients moving during treatment

NCT ID NCT07627022

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a smartphone reminder app can help lung cancer patients stay physically active during radiation therapy. About 32 adults with lung cancer will use the app or standard care, and their daily step counts will be compared. The goal is to see if simple digital reminders can improve activity levels during treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically proven lung cancer 2. Treatment with ≥50 Gy of conventionally fractionated radiation therapy 3. Possession of and ability to use a smart phone plus a step counter 4. Age ≥18 years 5. Written informed consent 6. Capacity of the patient to consent Exclusion Criteria: 1\. Expected non-compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Oncology Vejle Hospital, University Hospital of Southern Denmark

    Vejle, 7100, Denmark

  • Department of Pulmonology, University of Luebeck

    Lübeck, Schleswig-Holstein, 23562, Germany

  • Department of Radiation Oncology, Christian-Albrechts University

    Kiel, Schleswig-Holstein, 24105, Germany

  • Department of Radiation Oncology, University of Luebeck

    Lübeck, Schleswig-Holstein, 23562, Germany

  • Department of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana

    Ljubljana, 1000, Slovenia

  • MVZ RON Niedersachsen Strahlentherapie GmbH

    Hanover, Lower Saxony, 30161, Germany

  • Radiation Oncology Department, Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    Tbilisi, 0177, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.